Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of SAR566658 in CA6-positive metastatic triple-negative breast cancer
NL-OMON46882Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of SAR566658 in triple-negative breast cancer (TNBC) (2 arms), sponsored by Sanofi. Primary endpoints: Objective response rate and Safety. Started Jul 2017; status: active, not recruiting.
02
Drugs
SAR566658
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON46882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46882.